TwinBeech Capital’s Dyne Therapeutics DYN Stock Holding History

TwinBeech Capital’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-115,341	Closed	-$1.46M	–	664
2025 Q3	$1.46M	Sell	115,341 -81,807	-41%	-$933K	0.06%	267
2025 Q2	$1.88M	Buy	197,148 +138,623	+237%	+$1.53M	0.04%	336
2025 Q1	$612K	Buy	+58,525	New	+$837K	0.01%	559

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

TwinBeech Capital's DYN Position: Q4 2025 in Review

TwinBeech Capital sold out of Dyne Therapeutics (DYN) in Q4 2025, closing a stake of 115,341 shares — an estimated $1.46M sold.

TwinBeech Capital first reported a position in DYN in Q1 2025 and held it in 3 quarters. The position peaked at $1.88M in Q2 2025. 232 funds tracked by Wall St. Rank hold DYN as of Q4 2025.

TwinBeech Capital reported no remaining Dyne Therapeutics position as of Q4 2025 after selling out during the quarter.
TwinBeech Capital sold 115,341 Dyne Therapeutics shares in Q4 2025, an estimated $1.46M.
TwinBeech Capital first reported a position in Dyne Therapeutics in Q1 2025 and held it in 3 quarters.
TwinBeech Capital's Dyne Therapeutics position peaked at $1.88M in Q2 2025.
232 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q4 2025.

Based on TwinBeech Capital's 13F filing for Q4 2025, filed 17 Feb 2026.